Forteo ® (teriparatide [rDNA origin] injection)

20-mcg daily dose in a 2.4-mL prefilled delivery device

The below information is provided in response to your request and may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above.

Traveling with FORTEO® (teriparatide [rDNA origin] injection)

The US marketed travel bag is designed to protect the FORTEO delivery device when traveling up to 36 cumulative hours total travel time per device.

The teriparatide travel bag is intended only for occasional use when traveling. Do not store the travel bag itself in the freezer or refrigerator. It is best to pack your travel bag right before you leave. Do not store the travel bag in a car trunk (Forteo Package Insert, 2012)

The total travel time allowed per device is 36 hours as long as

  • the provided travel bag is used for traveling with the teriparatide delivery device and

  • the temperature that the teriparatide is exposed to during travel does not exceed 77°F or 25°C (room temperature) (Data on file).

Return the teriparatide delivery device to refrigeration as soon as possible when arriving at your travel destination. Except for traveling, store your teriparatide in the refrigerator at all times between 36°F and 46°F (2°C and 8°C). Do not expose it to freezing temperatures (Forteo Package Insert, 2012).

Travel by Air

A little advanced planning is needed when you travel by air with teriparatide. Before you travel, make sure you have a copy of your teriparatide prescription label. You may be asked to verify that the teriparatide Delivery Device and needles belong to you (Transportation Security Administration [WWW]).

Bring your teriparatide travel bag with you onto the airplane as a carry-on. The temperature in the checked luggage area is not always controlled and may become too hot or cold (Transportation Security Administration [WWW]).

A recent study demonstrated that x-ray radiation from screening equipment used in airport scanners did not impact the physical or chemical properties of teriparatide (Data on file).

Enclosed Prescribing Information

FORTEOÒ (teriparatide [rDNA origin] injection), Lilly

References

Data on file, Eli Lilly and Company and/or one of its subsidiaries.

FORTEO [package insert]. Indianapolis, IN: Eli Lilly and Company; 2012.

Transportation Security Administration website. Travelers with disabilities and medical conditions. Available at: http://www.tsa.gov/travelers/airtravel/specialneeds/index.shtm. Accessed February 26, 2018.

Date of Last Review: February 26, 2018

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 8pm ET

Or you can

Ask us a question Chat with us

Submit a question

Visit Us @LillyMedical